Lipodystrophy and human immunodeficiency virus infection

Shu Jan Lan

Research output: Contribution to journalArticle

Abstract

Human immunodeficiency virus (HIV)/acquired human immunodeficiency syndrome (AIDS) is a major public health problem worldwide, since it is the number one leading cause of death in certain underdeveloped countries. Although many anti-HIV drugs, which dramatically decrease morbidity and mortality associated with HIV/AIDS, are available in developed countries, long-term use of these drugs has been associated with the undesirable side effect of lipodystrophy, a very hot issue over the past 2-3 years in those countries. This review includes the following: 1) a review of the epidemic of HIV/AIDS in Taiwan as well as worldwide; 2) a definition, classification, and the characteristics of lipodystrophy; 3) the prevalence of lipodystrophy in people living with HIV (PLWH); 4) factors associated with lipodystrophy in PLWH such as HIV, antiretroviral drugs including protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTIs), non nucleoside reverse transcriptase inhibitors (NNRTIs), and other drugs; the duration of drug therapy and drug tolerability, gender, body mass index (BMI) and body composition, age, immunity, hormones, diet/nutrition, and exercise; 5) the influence of lipodystrophy on PLWH; and 6) treatments for lipodystrophy including switching therapies or stopping drugs, diet/nutrition therapies, exercise, drug therapies to lower blood lipid or glucose, hormonal therapy, and plastic surgery such as liposuction, lipectomy or fat grafts. For those with dyslipidemia, hyperglycemia, insulin resistance, or diabetes mellitus, in addition to the therapies of diet/nutrition and exercise, blood lipid- or glucose-lowering drugs can be used.

Original languageEnglish
Pages (from-to)118-128
Number of pages11
JournalNutritional Sciences Journal
Volume27
Issue number3
Publication statusPublished - Sep 2002

Fingerprint

Lipodystrophy
Human immunodeficiency virus
HIV infections
Virus Diseases
HIV
drugs
immunosuppression
Pharmaceutical Preparations
exercise
RNA-directed DNA polymerase
nucleosides
Nutrition Therapy
nutrition
Diet Therapy
Lipectomy
Exercise Therapy
blood lipids
therapeutics
blood glucose
Acquired Immunodeficiency Syndrome

Keywords

  • Acquired human immunodeficiency syndrome
  • AIDS
  • Antiretroviral drugs
  • HIV
  • Human immunodeficiency virus
  • Lipodystrophy

ASJC Scopus subject areas

  • Food Science
  • Medicine (miscellaneous)

Cite this

Lipodystrophy and human immunodeficiency virus infection. / Lan, Shu Jan.

In: Nutritional Sciences Journal, Vol. 27, No. 3, 09.2002, p. 118-128.

Research output: Contribution to journalArticle

Lan, Shu Jan. / Lipodystrophy and human immunodeficiency virus infection. In: Nutritional Sciences Journal. 2002 ; Vol. 27, No. 3. pp. 118-128.
@article{208330102b9f469693740f0c49efaa3d,
title = "Lipodystrophy and human immunodeficiency virus infection",
abstract = "Human immunodeficiency virus (HIV)/acquired human immunodeficiency syndrome (AIDS) is a major public health problem worldwide, since it is the number one leading cause of death in certain underdeveloped countries. Although many anti-HIV drugs, which dramatically decrease morbidity and mortality associated with HIV/AIDS, are available in developed countries, long-term use of these drugs has been associated with the undesirable side effect of lipodystrophy, a very hot issue over the past 2-3 years in those countries. This review includes the following: 1) a review of the epidemic of HIV/AIDS in Taiwan as well as worldwide; 2) a definition, classification, and the characteristics of lipodystrophy; 3) the prevalence of lipodystrophy in people living with HIV (PLWH); 4) factors associated with lipodystrophy in PLWH such as HIV, antiretroviral drugs including protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTIs), non nucleoside reverse transcriptase inhibitors (NNRTIs), and other drugs; the duration of drug therapy and drug tolerability, gender, body mass index (BMI) and body composition, age, immunity, hormones, diet/nutrition, and exercise; 5) the influence of lipodystrophy on PLWH; and 6) treatments for lipodystrophy including switching therapies or stopping drugs, diet/nutrition therapies, exercise, drug therapies to lower blood lipid or glucose, hormonal therapy, and plastic surgery such as liposuction, lipectomy or fat grafts. For those with dyslipidemia, hyperglycemia, insulin resistance, or diabetes mellitus, in addition to the therapies of diet/nutrition and exercise, blood lipid- or glucose-lowering drugs can be used.",
keywords = "Acquired human immunodeficiency syndrome, AIDS, Antiretroviral drugs, HIV, Human immunodeficiency virus, Lipodystrophy",
author = "Lan, {Shu Jan}",
year = "2002",
month = "9",
language = "English",
volume = "27",
pages = "118--128",
journal = "Journal of the Chinese Nutrition Society",
issn = "1011-6958",
publisher = "臺灣營養學會",
number = "3",

}

TY - JOUR

T1 - Lipodystrophy and human immunodeficiency virus infection

AU - Lan, Shu Jan

PY - 2002/9

Y1 - 2002/9

N2 - Human immunodeficiency virus (HIV)/acquired human immunodeficiency syndrome (AIDS) is a major public health problem worldwide, since it is the number one leading cause of death in certain underdeveloped countries. Although many anti-HIV drugs, which dramatically decrease morbidity and mortality associated with HIV/AIDS, are available in developed countries, long-term use of these drugs has been associated with the undesirable side effect of lipodystrophy, a very hot issue over the past 2-3 years in those countries. This review includes the following: 1) a review of the epidemic of HIV/AIDS in Taiwan as well as worldwide; 2) a definition, classification, and the characteristics of lipodystrophy; 3) the prevalence of lipodystrophy in people living with HIV (PLWH); 4) factors associated with lipodystrophy in PLWH such as HIV, antiretroviral drugs including protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTIs), non nucleoside reverse transcriptase inhibitors (NNRTIs), and other drugs; the duration of drug therapy and drug tolerability, gender, body mass index (BMI) and body composition, age, immunity, hormones, diet/nutrition, and exercise; 5) the influence of lipodystrophy on PLWH; and 6) treatments for lipodystrophy including switching therapies or stopping drugs, diet/nutrition therapies, exercise, drug therapies to lower blood lipid or glucose, hormonal therapy, and plastic surgery such as liposuction, lipectomy or fat grafts. For those with dyslipidemia, hyperglycemia, insulin resistance, or diabetes mellitus, in addition to the therapies of diet/nutrition and exercise, blood lipid- or glucose-lowering drugs can be used.

AB - Human immunodeficiency virus (HIV)/acquired human immunodeficiency syndrome (AIDS) is a major public health problem worldwide, since it is the number one leading cause of death in certain underdeveloped countries. Although many anti-HIV drugs, which dramatically decrease morbidity and mortality associated with HIV/AIDS, are available in developed countries, long-term use of these drugs has been associated with the undesirable side effect of lipodystrophy, a very hot issue over the past 2-3 years in those countries. This review includes the following: 1) a review of the epidemic of HIV/AIDS in Taiwan as well as worldwide; 2) a definition, classification, and the characteristics of lipodystrophy; 3) the prevalence of lipodystrophy in people living with HIV (PLWH); 4) factors associated with lipodystrophy in PLWH such as HIV, antiretroviral drugs including protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTIs), non nucleoside reverse transcriptase inhibitors (NNRTIs), and other drugs; the duration of drug therapy and drug tolerability, gender, body mass index (BMI) and body composition, age, immunity, hormones, diet/nutrition, and exercise; 5) the influence of lipodystrophy on PLWH; and 6) treatments for lipodystrophy including switching therapies or stopping drugs, diet/nutrition therapies, exercise, drug therapies to lower blood lipid or glucose, hormonal therapy, and plastic surgery such as liposuction, lipectomy or fat grafts. For those with dyslipidemia, hyperglycemia, insulin resistance, or diabetes mellitus, in addition to the therapies of diet/nutrition and exercise, blood lipid- or glucose-lowering drugs can be used.

KW - Acquired human immunodeficiency syndrome

KW - AIDS

KW - Antiretroviral drugs

KW - HIV

KW - Human immunodeficiency virus

KW - Lipodystrophy

UR - http://www.scopus.com/inward/record.url?scp=0036753530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036753530&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 118

EP - 128

JO - Journal of the Chinese Nutrition Society

JF - Journal of the Chinese Nutrition Society

SN - 1011-6958

IS - 3

ER -